How to Calculate GLP-1 A1C Reduction Estimator

What is GLP-1 A1C Reduction Estimator?

The GLP-1 A1C Reduction Estimator predicts the expected decrease in hemoglobin A1C for type 2 diabetes patients starting GLP-1 receptor agonist therapy. Based on clinical trial data, it accounts for baseline A1C, medication choice, dose, and concurrent diabetes medications.

Formula

Estimated A1C Reduction = Baseline A1C Adjustment Factor × Medication Efficacy Coefficient

A1C₀: Baseline A1C (%) — Starting hemoglobin A1C before GLP-1 initiation
ΔA1C: A1C Reduction (% points) — Expected absolute decrease in A1C
D: GLP-1 Dose (mg/week) — Maintenance dose of selected GLP-1 medication
T: Time on Treatment (months) — Duration of GLP-1 therapy (most reduction occurs within 6 months)

Step-by-Step Guide

1Enter your current A1C level and type 2 diabetes medications
2Select the GLP-1 medication and target dose
3The calculator estimates A1C reduction at 6 and 12 months based on trial data
4View your projected A1C alongside ADA target ranges (<7% for most adults)

Worked Examples

Input

Baseline A1C: 8.5%, starting semaglutide 1.0 mg (Ozempic), currently on metformin

Result

Expected A1C reduction: -1.4 to -1.8%. Projected A1C at 6 months: 6.7-7.1%. Likely to reach ADA target of <7%.

Input

Baseline A1C: 9.2%, starting tirzepatide 15 mg (Mounjaro), on metformin + SGLT2i

Result

Expected A1C reduction: -2.0 to -2.4%. Projected A1C at 6 months: 6.8-7.2%. SURPASS trials showed 2.07% reduction at this dose.

Common Mistakes to Avoid

✕Expecting immediate A1C improvement — A1C reflects a 3-month glucose average, so meaningful changes take 3-6 months
✕Not accounting for the fact that higher baseline A1C levels tend to show larger absolute reductions
✕Stopping other diabetes medications without provider guidance when A1C improves on GLP-1 therapy

Frequently Asked Questions

How long does it take for GLP-1 medication to lower A1C?

Most patients see A1C improvement starting at the first check (3 months), with maximum reduction typically achieved by 6 months. Since A1C reflects a 3-month rolling average of blood glucose, it takes at least one full cycle to see the full effect of dose titration.

Can GLP-1 therapy bring A1C to normal levels?

Many patients achieve A1C below 7% (ADA target), and some reach below 6.5% (near-normal). In the SURPASS-2 trial, up to 86% of tirzepatide 15 mg patients achieved A1C <7%. However, results depend heavily on baseline A1C, concurrent medications, diet, and exercise.

Ready to calculate? Try the free GLP-1 A1C Reduction Estimator Calculator

Try it yourself →